Core Viewpoint - Agna Biopharmaceuticals, a Chinese biotech company, is planning an IPO in Hong Kong with potential fundraising of several hundred million dollars [1] Company Overview - Agna Biopharmaceuticals was established in 2021 and is headquartered in Guangzhou, Guangdong Province [1] - The company focuses on RNAi drugs and mRNA vaccines, leveraging the potential of RNA and its diverse RNA combinations along with efficient drug delivery systems [1] - Agna is developing RNA drugs and vaccines for infectious diseases, metabolic diseases, cardiovascular diseases, malignant tumors, and rare diseases [1] Production Capacity - With support from the local government, Agna has built an advanced production line capable of producing over 500 million doses of mRNA vaccines annually [1] IPO Details - The company is collaborating with major investment banks including Bank of America, CICC, Jefferies, and JPMorgan for its IPO [1] - Agna has submitted a confidential IPO application, with specific details regarding scale and timing still under discussion [1]